Matinas BioPharma Holdings Inc (MTNB)
0.6344
-0.08
(-10.65%)
USD |
NYAM |
Nov 14, 16:00
0.6306
0.00 (0.00%)
After-Hours: 20:00
Matinas BioPharma Holdings Research and Development Expense (Quarterly): 3.371M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.371M |
| March 31, 2024 | 3.446M |
| December 31, 2023 | 3.665M |
| September 30, 2023 | 3.295M |
| June 30, 2023 | 3.559M |
| March 31, 2023 | 3.97M |
| December 31, 2022 | 3.867M |
| September 30, 2022 | 3.707M |
| June 30, 2022 | 4.127M |
| March 31, 2022 | 4.978M |
| December 31, 2021 | 4.240M |
| September 30, 2021 | 4.621M |
| June 30, 2021 | 2.481M |
| March 31, 2021 | 3.241M |
| December 31, 2020 | 3.526M |
| September 30, 2020 | 3.336M |
| June 30, 2020 | 3.410M |
| March 31, 2020 | 4.087M |
| December 31, 2019 | 3.420M |
| September 30, 2019 | 2.671M |
| June 30, 2019 | 2.829M |
| March 31, 2019 | 2.315M |
| December 31, 2018 | 1.692M |
| Date | Value |
|---|---|
| September 30, 2018 | 1.380M |
| June 30, 2018 | 1.523M |
| March 31, 2018 | 2.193M |
| December 31, 2017 | 2.298M |
| September 30, 2017 | 2.013M |
| June 30, 2017 | 2.315M |
| March 31, 2017 | 2.384M |
| December 31, 2016 | 1.548M |
| September 30, 2016 | 0.8353M |
| June 30, 2016 | 0.6426M |
| March 31, 2016 | 0.9217M |
| December 31, 2015 | 1.610M |
| September 30, 2015 | 0.8792M |
| June 30, 2015 | 1.355M |
| March 31, 2015 | 1.448M |
| December 31, 2014 | 1.914M |
| September 30, 2014 | 1.070M |
| June 30, 2014 | 1.118M |
| March 31, 2014 | 1.074M |
| December 31, 2013 | 0.7268M |
| September 30, 2013 | 0.745M |
| June 30, 2013 | 0.2401M |
| March 31, 2013 | 0.0496M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.481M
Minimum
Jun 2021
4.978M
Maximum
Mar 2022
3.702M
Average
3.559M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Equillium Inc | 10.81M |
| Tenon Medical Inc | 0.708M |
| Alphatec Holdings Inc | 20.36M |
| Merck & Co Inc | 5.862B |
| Madrigal Pharmaceuticals Inc | 68.74M |